Renzapride

Renzapride
Clinical data
ATC code
  • none
Identifiers
  • 4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H22ClN3O2
Molar mass323.82 g·mol−1
3D model (JSmol)
  • Clc1cc(c(OC)cc1N)C(=O)N[C@@H]3CC[N@]2C[C@@H]3CCC2
  • InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14+/m0/s1 checkY
  • Key:GZSKEXSLDPEFPT-IINYFYTJSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist.[1][2] It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors.[1]

Renzapride was being developed by Alizyme plc of the United Kingdom. In May 2016, EndoLogic LLC, a US-based pharmaceutical and medical device company, acquired the US and worldwide patent rights to Renzapride.

Endologic confirmed the cardiac safety of renzapride through a “Thorough QTc” study [3] and sold the rights to Atlantic Healthcare plc in 2019,[4] a specialist pharmaceutical company.

Atlantic Healthcare is focusing on the development of renzapride for the management of gastrointestinal (GI) motility in a number of rare diseases, including systemic scleroderma and cystic fibrosis, both of which are associated with chronic GI motility problems and for which there are no approved therapies.

  1. ^ a b Meyers NL, Hickling RI (2008). "Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome". Drugs in R&D. 9 (1): 37–63. doi:10.2165/00126839-200809010-00004. PMC 7044400. PMID 18095752.
  2. ^ Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, et al. (October 2004). "Effect of renzapride on transit in constipation-predominant irritable bowel syndrome". Clinical Gastroenterology and Hepatology. 2 (10): 895–904. doi:10.1016/s1542-3565(04)00391-x. PMID 15476153.
  3. ^ "FDA accepts cardiac safety trial for gastroparesis drug". Healio. 21 May 2018. Archived from the original on 12 July 2019. Retrieved 12 July 2019.
  4. ^ Quested T (26 June 2019). "Atlantic Healthcare pounces on big bucks US opportunity". Business Weekly. Archived from the original on 1 July 2019. Retrieved 12 July 2019.